QuickChek – November 18, 2021



Eagle Bulk Shipping Inc. Announces the Appointment of a Chief Strategy Officer

Eagle Bulk Shipping announced that Costa Tsoutsoplides has been appointed as the Company’s Chief Strategy Officer

Research, News & Market Data on Eagle Bulk Shipping

Watch recent presentation from Eagle Bulk Shipping



Comtech Telecommunications Corp. Awarded $1.7 Million Contract Renewal with U.S. Tier-One Mobile Network Operator

Comtech Telecommunications announced that during its first quarter of fiscal 2022, it was awarded a $1.7 million renewal agreement with a U.S. tier-one mobile network operator

Research, News & Market Data on Comtech

Watch recent presentation from Comtech



The Voyager Token (VGX) Listed on Coinbase Pro

Voyager Digital announced the Voyager token (VGX) is now listed on Coinbase Pro

Research, News & Market Data on Voyager Digital

Watch recent presentation from Voyager Digital



Chakana Intersects 10m with 15.48 g/t Gold, 1.27% Copper and 82.4 g/t Silver (18.50 G/t Au-eq or 12.09% Cu-eq) within 237m of 1.74 g/t Gold, 0.59% Copper and 25.2 g/t Silver in Breccia Pipe 5 from Surface at Soledad, Peru

Chakana Copper announced results from the remaining twelve resource definition holes drilled in Bx 5

Research, News & Market Data on Chakana Copper

Watch recent presentation from Chakana Copper

 

Stay up to date. Follow us:

 

Release – Chakana Intersects 10m in Breccia Pipe 5 from Surface at Soledad Peru


Chakana Intersects 10m with 15.48 g/t Gold, 1.27% Copper and 82.4 g/t Silver (18.50 G/t Au-eq or 12.09% Cu-eq) within 237m of 1.74 g/t Gold, 0.59% Copper and 25.2 g/t Silver in Breccia Pipe 5 from Surface at Soledad, Peru

 

Soledad
Project Highlights Include:

  • Reporting 12 remaining resource definition
    holes totalling 2,541m at Breccia Pipe 5 (Bx 5), all with significant intercepts.
  • Additional resource definition drill
    results pending for Huancarama.
  • Off-set IP surveys continue over all high
    priority targets defined to date.

 

Vancouver, B.C., November 18, 2021 – Chakana Copper Corp. (TSX-V: PERU;
OTCQB: CHKKF; FRA: 1ZX)
(the Company or
Chakana”), is pleased to provide results from the remaining twelve resource definition holes drilled in Bx 5 totaling 2,541m at the Soledad project, Ancash, Peru (see table below). This resource drilling is part of the fully funded 26,000m exploration and resource drilling program planned for 2021 (Fig. 1).  These results will further increase confidence in the initial resource estimate, anticipated to be completed by the end of 2021.

“The
final resource definition drill results released today for Bx 5 are an
outstanding culmination of the drilling on this breccia pipe. In addition to
the very strong mineralization that starts at surface, we now have
mineralization confirmed to a depth of 485m at Bx 5 where the breccia pipe and
mineralization are open at depth. Bx 5 is known to have very consistent and
continuous mineralization with zones of very high grades surrounded by long
runs of strong copper, gold, and silver grades. The breccia pipe plunges
slightly to the east from surface to 200m depth, then plunges gently north in
the direction of Bx 6. The area between Bx 5 and Bx 6 is highly prospective for
the discovery of additional breccia-hosted mineralization. With this release,
all resource definition drill results for Bx 5 have been published. We have
pending resource definition drill results for Huancarama to publish leading up
to the first ever National Instrument 43-101 compliant resource estimate for
the Soledad project,”
stated President and CEO David Kelley.

Drill Results

Bx 5 (Resource Definition)


DDH #

From      –     To (m)

Core Length (m)

Au

g/t

Ag

g/t

Cu

%

Cu-eq
%*

Au-eq g/t*

SDH21-244

0.00

155.00

155.00

1.41

26.2

0.30

1.45

2.21

SDH21-252

0.00

97.00

97.00

0.77

24.9

0.18

0.90

1.37

SDH21-253

0.00

106.00

106.00

1.24

31.5

0.32

1.40

2.14

SDH21-255

0.00

123.00

123.00

1.23

29.3

0.36

1.41

2.16

and

132.00

141.00

9.00

1.28

24.6

0.36

1.41

2.15

and

158.00

194.00

36.00

0.63

14.6

0.56

1.10

1.68

SDH21-256

0.00

237.00

237.00#

1.74

25.2

0.59

1.94

2.97

including

0.00

105.00

105.00

1.15

26.0

0.27

1.24

1.90

including

105.00

115.00

10.00

15.48

82.4

1.27

12.09

18.50

including

115.00

237.00

122.00

1.12

19.8

0.81

1.71

2.62

SDH21-258

0.00

92.00

92.00

1.32

40.0

0.37

1.57

2.41

SDH21-260

0.00

147.00

147.00

1.36

24.8

0.30

1.40

2.14

SDH21-261

0.00

92.00

92.00

1.42

43.1

0.34

1.64

2.50

SDH21-262

0.00

160.00

160.00

1.80

24.5

0.32

1.71

2.61

SDH21-264

0.00

121.80

121.80

1.34

33.3

0.30

1.46

2.23

SDH21-270

339.80

343.00

3.20

7.82

60.2

0.97

6.60

10.09

and

390.20

414.00

23.80

0.16

6.3

0.71

0.87

1.33

SDH21-272

313.00

417.00

104.00

0.48

10.1

1.38

1.78

2.72

and

432.00

438.00

6.00

0.21

2.2

1.06

1.22

1.86

and

447.00

485.65

38.65

0.26

8.1

1.12

1.36

2.08

* Cu_eq and Au_eq values were calculated using copper, gold, and silver. Metal prices utilized for the calculations are Cu – US$2.90/lb, Au – US$1,300/oz, and Ag – US$17/oz. No adjustments were made for recovery as the project is an early-stage exploration project and metallurgical data to allow for estimation of recoveries are not yet available. The formulas utilized to calculate equivalent values are Cu-eq (%) = Cu% + (Au g/t * 0.6556) + (Ag g/t * 0.00857) and Au-eq (g/t) = Au g/t + (Cu% * 1.5296) + (Ag g/t * 0.01307). # SDH21-256 is mineralized from surface to 237m; for greater clarity the analytical results are also reported in three separate intervals so as to identify a high-grade interval from 105 to 115m.

Bx 5

The Bx 5 breccia pipe is in the north-central part of the project and is one of six breccia pipes that will be included in our initial resource estimate (Fig. 1). The breccia pipe forms a prominent monument outcrop and extends to depths greater than 485m where mineralization remains open. Drill holes described in this release were designed to confirm shallow mineralization in the top southeastern quadrant of the breccia pipe, as well as deeper extents of mineralization probed by two holes drilled to the north from a platform located 100m south of the breccia pipe (Figs. 2 and 3). All holes intersected significant mineralization (see Figure 4 for select core photos of the mineralization).

 

2021 Resource and
Exploration Drill Program

A total of 23,947m of drilling has been completed in 2021. The objectives of this drill program are to complete resource definition drilling on six initial breccia pipes to an approximate depth of 300m and test several new exploration targets. Breccia pipes that will be included in the initial resource estimate are: Bx1, Bx 5, Bx6, Paloma East, Paloma West, and Huancarama (Fig. 1). Additional resource definition drill results for Huancarama are pending. During 2021 our drilling was focused on the north half of the project where drill permits are in place. Permitting for the south half of the project is well advanced. The southern half of the property hosts several outcropping mineralized tourmaline breccia pipes and has been recently covered by the Company’s ongoing geophysical program. Numerous targets exist, none of which have been drilled previously.

 

Geophysical Surveys

Gradient-array induced-polarization (IP) surveys have been completed over the entire 12km2 footprint of the Soledad mineral system. Off-set IP surveys are now in-progress covering high priority target areas. This work complements the extensive exploration database that supports our current inventory of 110 exploration targets. This new information identifies both new targets and prioritizes existing targets that will be tested when the exploration drilling programs resume. 

 

About Chakana Copper

Chakana Copper Corp is a Canadian-based minerals exploration company that is currently advancing the Soledad Project located in the Ancash region of Peru, a highly favorable mining jurisdiction with supportive communities. The Soledad Project is notable for the high-grade copper-gold-silver mineralization that is hosted in tourmaline breccia pipes. A total of 60,854 metres in 261 diamond core holes for exploration and resource definition drilling have been completed since 2017, testing 16 of 110 total exploration targets, confirming that Soledad is a large, well-endowed mineral system with strong exploration upside. Chakana’s investors are uniquely positioned as the Soledad Project provides exposure to base and precious metals. For more information on the Soledad project, please visit the website at www.chakanacopper.com.

 

Sampling and Analytical Procedures

Chakana follows rigorous sampling and analytical protocols that meet or exceed industry standards. Core samples are stored in a secured area until transport in batches to the ALS facility in Callao, Lima, Peru.  Sample batches include certified reference materials, blank, and duplicate samples that are then processed under the control of ALS. All samples are analyzed using the ME-MS41 (ICP technique that provides a comprehensive multi-element overview of the rock geochemistry), while gold is analyzed by AA24 and GRA22 when values exceed 10 g/t by AA24.  Over limit silver, copper, lead and zinc are analyzed using the OG-46 procedure. Soil samples are analyzed by 4-acid (ME-MS61) and for gold by Fire Assay on a 30g sample (Au-ICP21).

Results of previous drilling and additional information concerning the Project, including a technical report prepared in accordance with National Instrument 43-101, are made available on Chakana’s SEDAR profile at www.sedar.com.

Qualified
Person

David Kelley, an officer and a director of Chakana, and a Qualified Person as defined by NI 43-101, reviewed and approved the technical information in this news release.

 

ON BEHALF OF THE BOARD

(signed) “David Kelley
David Kelley
President and CEO

 

For further information contact:

Joanne Jobin, Investor Relations Officer

Phone:   647 964 0292
Email:    jjobin@chakanacopper.com

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the Exchange) accepts responsibility
for the adequacy or accuracy of this release.

 

Forward-looking Statement Advisory: This release may contain forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance, or achievements of Chakana to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Forward looking statements or information relates
to, among other things, the interpretation of the nature of the mineralization
at the
 Soledad copper-gold-silver project
(the “Project”), the potential to expand the mineralization, and
to develop and grow a resource within the Project, the
planning for further exploration work, the ability to de-risk the potential
exploration targets, and our belief in the potential
for mineralization within unexplored parts of the Project. These
forward-looking statements are based on management’s current expectations and
beliefs but given the uncertainties, assumptions and risks, readers are
cautioned not to place undue reliance on such forward- looking statements or
information. The Company disclaims any obligation to update, or to publicly
announce, any such statements, events or developments except as required by
law.

 

Figure 1 – View looking north showing outcropping breccia pipes and occurrences within the northern Soledad cluster. Pipes that will be included in the initial resource are shown in green (Bx 1, Bx 5, Bx 6, Paloma East, Paloma West, and Huancarama). Breccia pipes shown in yellow have had exploration drilling completed. Other pipes/occurrences and targets defined by other exploration data remain to be tested by drilling. Additional breccia pipes occur on the south half of the property and are not shown here.  

 

Figure 2 – Map showing drill holes reported in this release and modeled breccia pipe (light red shape) based on all drill holes. Light gray contours are at 10m intervals. Blue rectangle in the inset map shows the area of Figure 2 within the overall Chakana property.

 

Figure 3 – 3D sectional view of Bx 5 looking west. Light red 3D shape shows breccia pipe geometry based on all drill holes. Previous holes drilled shown in grey traces.

 

Figure 4 – Select core photos from Bx 5 reported in this release: SDH21-244 (34.7m) shingle breccia cemented with chalcopyrite-pyrite; SDH21-252 (33.9m) chaotic shingle breccia with chalcopyrite-pyrite in matrix; SDH21-253 (41.5m) chaotic shingle breccia with chalcopyrite-pyrite in matrix; SDH21-255 (39.6m) shingle breccia cemented with chalcopyrite-pyrite; SDH21-256 (110.55m) chaotic shingle breccia with semi-massive chalcopyrite-pyrite; SDH21-258 (35.45m) shingle breccia cemented with chalcopyrite-pyrite; SDH21-261 (39.25m) chaotic shingle breccia with semi-massive chalcopyrite-pyrite. Core diameter is 6.35cm (HQ) in all instances.

Euroseas (ESEA) – Stock Price Weakness Doesn’t Match Slight Miss

Wednesday, November 17, 2021

Euroseas (ESEA)
Stock Price Weakness Doesn’t Match Slight Miss

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    A Slight Miss. Adjusted 3Q2021 EBITDA of $10.6 million included dry dock expenses of $2.7 million. After adding back dry dock expenses, our adjusted 3Q2021 EBITDA of $13.3 million was slightly below expectations of $13.8 million due to higher opex costs.

    Adjusting 2021 EBITDA estimate to incorporate 3Q2021 results.  Fine tuning our 2021 EBITDA estimate to $53.9 million based on TCE rates of $18.6k/day to reflect 3Q2021 operating results and slightly higher opex. As discussed in our most recent note, forward cover is full and the Corfu is repositioning toward China on a short charter prior to dry docking …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

TAAL Distributed Information Technologies (TAALF) – Strong 3Q21; Raising PT

Wednesday, November 17, 2021

TAAL Distributed Information Technologies (TAALF)
Strong 3Q21; Raising PT

Taal Distributed Information Technologies Inc delivers value-added blockchain services, providing professional-grade, highly scalable blockchain infrastructure and transactional platforms to support businesses building solutions and applications upon the Bitcoin SV platform, and developing, operating, and managing distributed computing systems for enterprise users.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    3Q21 Results. TAAL had previously pre-announced 3Q revenue in the $11.5-$12.0 million (CAD) range. Actual revenue came in at $12.4 million, with income before value adjustments of $8.0 million, adjusted EBITDA of $3.9 million, and net income of $2.1 million, or $0.05 per share. We had projected revenue of $8 million, income before value adjustments of $4.8 million, and a net loss of $725,000, or $0.02 per share.

    Transactions.  TAAL processed over 52 million transactions on BSV in the quarter, earning $411,000 from transaction processing fees in the quarter, or 3% of total revenue. While mining continues to be the near-term revenue driver, we expect transaction fees to be the long-term value driver of the stock …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Cancer’s Predator-Prey Relationship with New Treatments and the Immune System


Image Credit: Jean van der Meulen (Pexels)

Cancers Are in an Evolutionary Battle with Treatments – Evolutionary Game Theory Could Tip the Advantage to Medicine

 

Cancer was the second leading cause of death in the U.S. in 2020. Although billions of dollars have been poured into cancer research, the results are still disappointing for many patients who pay hundreds of thousands of dollars to extend their lives for just a few more months. But why do cancer therapies fail?

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of, Anuraag Bukkuri, PhD Student in Integrated Mathematical Oncology, University of South Florida

 

I’m a doctoral student at the Moffitt Cancer Center and the University of South Florida who develops and applies mathematical and evolutionary theories to understand how cancer works and how to best treat it. And I believe that approaching cancer treatment through the lens of ecology and evolution may help doctors and researchers grapple with this question and fight more effectively against cancer.

Cancer can be seen as being in a predator-prey relationship with the immune system of the body, where cancer is the prey and the immune system is the predator.

 

Standard Treatment Protocols

For decades, standard treatment for cancer involved bombarding patients with the maximum tolerable dose of a drug, attempting to kill as many cancer cells as possible while minimizing adverse side effects.

However, the cancer cells that make up a tumor are not all the same. By random chance, some of these cells develop mutations, or alterations in the cell’s genetic material, that make them immune to a drug. These cells can then proliferate and repopulate the tumor, leading to therapeutic resistance that renders the drug ineffective.

When this occurs, physicians typically switch to another drug that targets a different aspect of the cancer cells. This continues until a therapy is able to effectively control the cancer or no more drugs are available, at which point patients are provided hospice care to make their last days as comfortable as possible.

This protocol has led to the development of a plethora of drugs that target specific features of the tumor’s biology, from boosting the body’s natural defense system to blocking chemical signals on the cancer cells to prevent them from growing. Though some of these drugs have proved to be incredibly effective in a subset of patients, this approach does not work for everyone.

 

The Role of Evolutionary Game Theory

To improve long-term outcomes for all patients, cancer researchers ask two critical questions: How do tumors grow, and how do they become resistant? Looking at cancer through the lens of ecology and evolution, or how the environment of the body molds and is molded by evolving cancer cells over time, can help answer these questions.

One way to think through this is with evolutionary game theory, which uses rigorous mathematics to try to predict how something will react to changes in its environment in a way that maximizes its fitness, or its ability to reproduce.

Evolutionary game theory can help
researchers understand the effect of selective pressures, which are external
factors that affect an organism’s survival. In the case of cancer, selective
pressures can be therapies, and EGT helps researchers understand their effects
on how cancer cells interact with one another and their environment.

For example, consider the principle of the double bind. In nature, this refers to how a prey’s tactic for avoiding one predator results in an increase in the prey’s susceptibility to another. For example, gerbils seek refuge from owls by hiding in bushes scattered across a desert. But snakes are waiting to strike under some of these bushes. The gerbil’s tactics to avoid one predator make it more vulnerable to the other.

Similarly, in cancer, therapies can be administered in a way that leads to a double bind by which the cancer’s growing resistance to one therapy leaves it more susceptible to other therapies. This puts the cancer in an evolutionary trap created from its own adaptations.

These mathematical models have paved the way for the development of therapies using principles from ecology and evolution to better treat and manage cancer. For example, one lung cancer clinical trial gave patients an immunotherapy, which teaches the body’s immune system to recognize and destroy cancer cells, followed by a chemotherapy, which kills cancer cells directly. Exposure to the first treatment sensitized the cancer cells to the second, making the combined treatments more effective than they would have been by themselves.

 

Looking Ahead

Evolutionary game theory can help researchers and oncologists more effectively predict how cancers will respond to different treatments and potentially control the evolutionary trajectory of cancer. This could help ensure optimal outcomes for patients.

While there has been a lot of progress in treating cancer, there’s still a long way to go to make all forms of cancer manageable diseases. One promising path to that goal is harnessing the power of evolution to keep the pressure on cancer.

 

Suggested Reading:



For Stem Cells, Bigger Doesn’t Mean Better



Pros and Cons of FDA Funded in Part by Companies





Attacking Tumors by Returning Cancer Cells to the Body



CPI and PPI Both Suggests Persistent Inflation

 

Stay up to date. Follow us:

 

Cancers Predator-Prey Relationship with New Treatments and the Immune System


Image Credit: Jean van der Meulen (Pexels)

Cancers Are in an Evolutionary Battle with Treatments – Evolutionary Game Theory Could Tip the Advantage to Medicine

 

Cancer was the second leading cause of death in the U.S. in 2020. Although billions of dollars have been poured into cancer research, the results are still disappointing for many patients who pay hundreds of thousands of dollars to extend their lives for just a few more months. But why do cancer therapies fail?

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of, Anuraag Bukkuri, PhD Student in Integrated Mathematical Oncology, University of South Florida

 

I’m a doctoral student at the Moffitt Cancer Center and the University of South Florida who develops and applies mathematical and evolutionary theories to understand how cancer works and how to best treat it. And I believe that approaching cancer treatment through the lens of ecology and evolution may help doctors and researchers grapple with this question and fight more effectively against cancer.

Cancer can be seen as being in a predator-prey relationship with the immune system of the body, where cancer is the prey and the immune system is the predator.

 

Standard Treatment Protocols

For decades, standard treatment for cancer involved bombarding patients with the maximum tolerable dose of a drug, attempting to kill as many cancer cells as possible while minimizing adverse side effects.

However, the cancer cells that make up a tumor are not all the same. By random chance, some of these cells develop mutations, or alterations in the cell’s genetic material, that make them immune to a drug. These cells can then proliferate and repopulate the tumor, leading to therapeutic resistance that renders the drug ineffective.

When this occurs, physicians typically switch to another drug that targets a different aspect of the cancer cells. This continues until a therapy is able to effectively control the cancer or no more drugs are available, at which point patients are provided hospice care to make their last days as comfortable as possible.

This protocol has led to the development of a plethora of drugs that target specific features of the tumor’s biology, from boosting the body’s natural defense system to blocking chemical signals on the cancer cells to prevent them from growing. Though some of these drugs have proved to be incredibly effective in a subset of patients, this approach does not work for everyone.

 

The Role of Evolutionary Game Theory

To improve long-term outcomes for all patients, cancer researchers ask two critical questions: How do tumors grow, and how do they become resistant? Looking at cancer through the lens of ecology and evolution, or how the environment of the body molds and is molded by evolving cancer cells over time, can help answer these questions.

One way to think through this is with evolutionary game theory, which uses rigorous mathematics to try to predict how something will react to changes in its environment in a way that maximizes its fitness, or its ability to reproduce.

Evolutionary game theory can help
researchers understand the effect of selective pressures, which are external
factors that affect an organism’s survival. In the case of cancer, selective
pressures can be therapies, and EGT helps researchers understand their effects
on how cancer cells interact with one another and their environment.

For example, consider the principle of the double bind. In nature, this refers to how a prey’s tactic for avoiding one predator results in an increase in the prey’s susceptibility to another. For example, gerbils seek refuge from owls by hiding in bushes scattered across a desert. But snakes are waiting to strike under some of these bushes. The gerbil’s tactics to avoid one predator make it more vulnerable to the other.

Similarly, in cancer, therapies can be administered in a way that leads to a double bind by which the cancer’s growing resistance to one therapy leaves it more susceptible to other therapies. This puts the cancer in an evolutionary trap created from its own adaptations.

These mathematical models have paved the way for the development of therapies using principles from ecology and evolution to better treat and manage cancer. For example, one lung cancer clinical trial gave patients an immunotherapy, which teaches the body’s immune system to recognize and destroy cancer cells, followed by a chemotherapy, which kills cancer cells directly. Exposure to the first treatment sensitized the cancer cells to the second, making the combined treatments more effective than they would have been by themselves.

 

Looking Ahead

Evolutionary game theory can help researchers and oncologists more effectively predict how cancers will respond to different treatments and potentially control the evolutionary trajectory of cancer. This could help ensure optimal outcomes for patients.

While there has been a lot of progress in treating cancer, there’s still a long way to go to make all forms of cancer manageable diseases. One promising path to that goal is harnessing the power of evolution to keep the pressure on cancer.

 

Suggested Reading:



For Stem Cells, Bigger Doesn’t Mean Better



Pros and Cons of FDA Funded in Part by Companies





Attacking Tumors by Returning Cancer Cells to the Body



CPI and PPI Both Suggests Persistent Inflation

 

Stay up to date. Follow us:

 

Release – Azarga Uranium Shareholders Approve Merger with enCore Energy


Azarga Uranium Shareholders Approve Merger with enCore Energy

 

VANCOUVER, BCNov. 17, 2021 /CNW/ – enCore Energy Corp. (TSXV: EU) (OTCQB: ENCUF) (the “Company” or “enCore”) is pleased to announce that the shareholders of Azarga Uranium Corp. (TSX: AZZ) (OTCQB: AZZUF) (FRA: P8AA) (“Azarga Uranium”) have approved the plan of arrangement (the “Plan of Arrangement”) with enCore previously announced on September 7th, 2021. The Plan of Arrangement was approved by 99.8% of the votes cast by holders of common shares of Azarga Uranium. enCore Energy will host an information session, via webinar, on Thursday, November 18, 2021 at 11 AM EST. Please register at: 

https://attendee.gotowebinar.com/register/5708536147519920651.

“enCore is very pleased with the results of the Azarga Uranium shareholder vote and will be working closely with Azarga to complete the next steps to close this transaction,” said William M. Sheriff, Executive Chairman. “Upon closing of this transaction, enCore Energy will have established itself as one of the leading in-situ recovery uranium development companies in the United States. The two licensed Texas production plants, now under revitalization, combined with over 90 million 43-101 compliant pounds of uranium resources across WyomingSouth Dakota and New Mexico1 ideally position enCore to advance clean energy sources in the nuclear renaissance.”

In addition, the Plan of Arrangement was approved by a simple majority of the votes cast by Azarga Uranium shareholders, excluding the votes cast in respect of the Azarga Uranium shares held by certain related parties (as defined by Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions).

The British Columbia Supreme Court hearing for the final order to approve the Plan of Arrangement is expected to occur on November 19, 2021. Closing of the Plan of Arrangement is subject to the receipt of applicable regulatory approvals and the satisfaction of certain other closing conditions customary in transactions of this nature, including, without limitation, the final stock exchange approval. enCore Energy and Azarga Uranium are working together to complete these regulatory approvals in order to close the transaction.

In connection with the Plan of Arrangement, the Azarga Uranium shareholders will receive 0.375 common shares of enCore for each Azarga Uranium common share held (the “Exchange Ratio”). Additionally, the Exchange Ratio will be subject to an adjustment mechanism at the closing of the transaction (the “Closing Exchange Ratio”). The Closing Exchange Ratio shall be equal to the greater of: (i) the Exchange Ratio; or (ii) an exchange ratio calculated as $0.54 divided by enCore’s 15-day volume-weighted average price prior to the closing of the transaction, subject to a maximum Closing Exchange Ratio of 0.49 common shares of enCore for each share of Azarga Uranium outstanding.

None of the securities to be issued pursuant to the transaction have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issuable in the transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

For further information, please see Azarga Uranium’s Report of Voting Results, which is filed on SEDAR at www.sedar.com

About Azarga Uranium Corp.

Azarga Uranium is an integrated uranium exploration and development company that controls ten uranium projects and prospects in the United States of America (“USA”) (South DakotaWyomingUtah and Colorado), with a primary focus of developing in-situ recovery uranium projects. The Dewey Burdock in-situ recovery uranium project in South Dakota, USA (the “Dewey Burdock Project”), which is the Company’s initial development priority, has been issued its Nuclear Regulatory Commission License and Class III and Class V Underground Injection Control permits from the Environmental Protection Agency and the Company is in the process of completing other major regulatory permit approvals necessary for the construction of the Dewey Burdock Project. For more information, please visit www.azargauranium.com.

About enCore Energy Corp.

enCore Energy Corp., a U.S. domestic uranium developer focused on becoming a leading in-situ recovery (“ISR”) uranium producer, is led by a team of industry experts with extensive knowledge and experience in all aspects of ISR uranium operations. enCore Energy’s initial opportunities are created from the Company’s South Texas licensed and past-producing Rosita and Kingsville Dome ISR production facilities, under development, and multiple satellite projects in South Texas plus the changing global uranium supply/demand outlook and opportunities for industry consolidation. Large uranium resource endowments in New Mexico add to the asset base for long term growth and development opportunities.

1. enCore Energy Corp. and Azarga Uranium Corp. News Release dated September 7, 2021.

SOURCE enCore Energy Corp

Release – Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels


Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels

 

EDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today reported preliminary results from the clinical study entitled “A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Compare the Efficacy and Safety of High-Medium Molecular Weight Beta-Glucan as Add-On to Statin Therapy in Subjects with Hyperlipidemia”. Following a protocol amendment, patients not treated with a statin were also eligible to enter the study.  

This clinical trial assessed the safety and efficacy of three dosages of oat beta glucan administered as 500 mg pills (1.5 g, 3 g and 6 g per day) compared to placebo. A total of 263 patients (169 females and 94 males) were enrolled in the study. The majority of patients did not receive a statin. The overall compliance to study pill intake was greater than 80%. From a safety perspective, there was no death and beta glucan was generally well tolerated.

The effect of oat beta glucan on the study primary endpoint of change in low-density lipoprotein cholesterol (LDL-C) was not statistically significant compared to placebo. Of note, amongst some positive findings observed with different parameters, there were dosage-related responses in weight and body-mass index at 12 weeks, but they also did not reach statistical significance.

“While we had hoped for a more definitive statistically significant outcome, many observations send some positive signals. They are in accordance with recent data by Cicero et al.1 on another beta glucan nutraceutical formulation and reinforce the hypothesis that oat beta glucan may offer appreciable health benefits, as indicated in Health Canada’s oat beta glucan approved monograph. While Ceapro’s oat beta glucan product complies with requirements for market authorization for a natural product and seeks to surpass marketed products, continued efforts may be warranted to explore its effect on weight and body-mass index with prolonged exposure and possibly higher dosage. The current study has been conducted under best clinical research practices by the expert team of the Montreal Heart Institute. I am very grateful for their great work, resilience, professionalism and competencies during this pandemic period,” commented Gilles R. Gagnon, Chief Executive Officer of Ceapro.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

1 Arrigo F. G. Cicero et al., « A Randomized Placebo-Controlled Clinical Trial to Evaluate the Medium-Term Effects of Oat Fibers on Human Health: The Beta-Glucan Effects on Lipid Profile, Glycemia and InTestinal Health (BELT) Study », Nutrients 12, no 3 (3 mars 2020): E686, https://doi.org/10.3390/nu12030686.

Release – Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights


Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights

 

– Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable therapeutic for COVID-19 –

 Q3 2021 record sales of $4,523,000 compared to $3,476,000 for Q3 2020, representing a 30% increase –

– Net profit of $875,000 for Q3 2021 vs. net profit of $192,000 for Q3 2020, a 356% increase –

 Achieved record production levels despite COVID-19 pandemic situation –

EDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and the first nine months ended September 30, 2021.

“Progress continues on all fronts from production operations to research and development, allowing us to advance our pipeline while expanding our business model. We are extremely proud of our employees who worked tirelessly since the beginning of the year to maintain operations and deliver these very solid results despite the COVID-19 pandemic. As we continue to move forward, our focus remains on the health and safety of our associates, followed by business continuity,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.

Corporate and Operational Highlights

Pipeline Development:

  • Pursued the development of new PGX-dried chemical complexes for potential applications under various forms like pills, capsules, fast dissolving strips and face masks. Alginate and yeast beta glucan to become key products of Ceapro’s portfolio.
  • Resumed bioavailability studies with University of Alberta for new chemical complexes yeast beta glucan-CoQ10, alginate-CoQ10 and newly formed alginate yeast beta glucan-CoQ10.
  • Announced research agreement with Boston-based Angiogenesis Foundation to assess in vivo bioefficacy of oat beta glucan and avenanthramides in angiogenesis, blood vessel repairs, wound healing and tissue regeneration in various inflammation-based diseases and conditions like COVID-19 presenting damages of the lung blood vessels.
  • Expanded collaboration with Montreal Heart Institute to initiate a Phase 1 clinical trial to assess safety and tolerability of pharmaceutical grade avenanthramides powder formulation.
  • Conducting in vivo studies with McMaster University with yeast beta glucan as a potential inhalable therapeutic.

Technology:

  • Pursued installment in Edmonton of a commercial scale unit for impregnation of bioactives with PGX-processed biopolymers.
  • Ongoing engineering design for PGX processing commercial unit.

Production Operations:

  • Achieved record levels with production of over 70 MT of finished products during the last quarter reliably providing our customers essential high quality products.

Subsequent to Quarter:

  • Announced discovery of a new mechanism of action for PGX processed yeast beta glucan (PGX-YBG) as a potential inhalable therapeutic for lung fibrotic diseases including COVID-19 patients.
    • PGX-YBG binds to specific receptors (Dectin 1) located on macrophages responsible for the cascade of immunomodulating events when activated.
    • McMaster’s research team demonstrates ability of PGX-YBG to reprogram macrophages on its own.
  • Reported preliminary results from clinical trial evaluating oat beta glucan in patients with high cholesterol levels. The study did not achieve the expected primary endpoint related to a decrease of low-density lipoproteins cholesterol when using Ceapro’s pill dosage form. While there was no statistically significant difference between the placebo group and the different dosages of beta glucan, there were positive signals that beta glucan nutraceutical formulation may offer appreciable health benefits as indicated with approved Health Canada’s beta glucan monograph (Natural Product Division)

Financial Highlights for the Third Quarter and Nine-Month Period Ended September 30, 2021

  • Total sales of $4,523,000 for the third quarter of 2021 and $13,633,000 for the first nine months of 2021 compared to $3,476,000 and $12,415,000 for the comparative periods in 2020. The 10% increase in sales for the first nine months is mainly due to a significant increase in sales of avenanthramides in the USA compared to the same period in 2020.
  • Net profit of $875,000 for the third quarter of 2021 and $2,067,000 for the first nine months of 2021 compared to a net profit of $192,000 and $2,395,000 for the comparative periods in 2020. Increased net profit for the third quarter of 2021 comes from improved margin of 65.2% as compared to 47.8% in 2020. Improved margins in 2021 result from the buying of excellent source material and from the diligent work of highly skilled personnel operating in only one site as compared to two sites in 2020.
  • R&D investments were $1,400,000 for Q3 2021 compared to $479,000 for the same period in 2020. The significant increase being due to payments made to Montreal Heart Institute for a clinical trial for the assessment of oat beta glucan as a potential cholesterol reducer by almost $1.0 million during Q3 2021.
  • Cash flows generated from operations of $2,837,000for the first nine months in 2021 vs $4,777,000 in 2020.
  • Positive working capital balance of $10,367,000 as of September 30, 2021.

“Looking ahead, while considering the ongoing potential economic impact related to COVID-19, evolving consumption trends and escalating inflationary levels we believe Ceapro is well-positioned to once again deliver a strong growth in sales well in line with the positive trend achieved over the last years. While we have experienced a “bump in the road” with the beta glucan trial, our solid base business and expanded pipeline will enable us to pursue the expansion of our business model to the nutraceutical sector with avenanthramides and yeast beta glucan for which we are going to conduct more preclinical assays before investing at large scale levels. With a strong balance sheet, a group of dedicated people, and a solid base business, coupled with the innovative technologies and products that we have developed to enable us to expand, Ceapro is poised to emerge as a successful life science company,” concluded Mr. Gagnon.

         
CEAPRO INC.        
Condensed Interim Consolidated Balance Sheets        
Unaudited        
         
  September 30,   December 31,  
  2021   2020  
  $   $  
         
ASSETS        
Current Assets        
Cash and cash equivalents 7,410,214   5,369,029  
Trade receivables 2,716,058   2,019,723  
Other receivables 39,522   102,224  
Inventories (note 3) 1,532,271   1,210,079  
Prepaid expenses and deposits 133,760   348,845  
         
Total Current Assets 11,831,825   9,049,900  
         
Non-Current Assets        
Investment tax credits receivable 607,700   607,700  
Deposits 82,124   82,124  
Licences (note 4) 16,292   18,514  
Property and equipment (note 5) 17,776,791   18,591,189  
Deferred tax assets 874,304   874,304  
         
Total Non-Current Assets 19,357,211   20,173,831  
         
TOTAL ASSETS 31,189,036   29,223,731  
         
LIABILITIES AND EQUITY        
Current Liabilities        
Accounts payable and accrued liabilities 1,097,645   1,067,622  
Current portion of lease liabilities (note 6) 286,608   250,658  
Current portion of CAAP loan (note 8) 80,811   72,263  
         
Total Current Liabilities 1,465,064   1,390,543  
         
Non-Current Liabilities        
Long-term lease liabilities (note 6) 2,432,682   2,648,917  
Deferred tax liabilities 874,304   874,304  
         
Total Non-Current Liabilities 3,306,986   3,523,221  
         
TOTAL LIABILITIES 4,772,050   4,913,764  
         
Equity        
Share capital (note 7 (b)) 16,557,401   16,511,067  
Contributed surplus (note 7 (e)) 4,676,456   4,682,393  
Retained earnings 5,183,129   3,116,507  
         
Total Equity 26,416,986   24,309,967  
         
TOTAL LIABILITIES AND EQUITY 31,189,036   29,223,731  


CEAPRO INC.
Condensed Interim Consolidated Statements of Net Income and Comprehensive Income
Unaudited
     
  Quarters   Nine Months  
  Ended September 30,   Ended September 30,  
  2021   2020   2021   2020  
  $   $   $   $  
           
Revenue (note 14) 4,522,980   3,475,625   13,633,354   12,414,970  
Cost of goods sold 1,573,655   1,814,080   5,787,608   5,794,573  
           
Gross margin 2,949,325   1,661,545   7,845,746   6,620,397  
           
Research and product development 1,403,186   478,993   3,050,544   1,381,332  
General and administration 766,605   791,217   2,431,659   2,494,514  
Sales and marketing 4,957   12,395   34,557   89,830  
Finance costs (note 11) 37,684   43,066   169,938   189,258  
           
Income from operations 736,893   335,874   2,159,048   2,465,463  
           
Other (expenses) income (note 10) 138,381   (144,251 ) (92,426 ) (70,746 )
           
Income before tax 875,274   191,623   2,066,622   2,394,717  
           
Income taxes        
           
Total comprehensive income for the period 875,274   191,623   2,066,622   2,394,717  
           
Net income per common share (note 17):          
Basic 0.01   0.00   0.03   0.03  
Diluted 0.01   0.00   0.03   0.03  
           
Weighted average number of common shares outstanding (note 17):          
Basic 77,684,017   77,610,113   77,669,747   77,585,679  
Diluted 78,740,532   78,700,415   78,694,469   78,039,105  


CEAPRO INC.
Condensed Interim Consolidated Statements of Cash Flows
Unaudited
     
  2021   2020  
Nine Months Ended September 30, $   $  
OPERATING ACTIVITIES    
Net income for the period 2,066,622   2,394,717  
Adjustments for items not involving cash    
Finance costs 106,390   117,237  
Transaction costs   1,108  
Depreciation and amortization 1,408,392   1,382,838  
Gain on disposal of equipment (5,000 )  
Accretion 8,548   15,913  
Share-based payments 13,672   122,902  
Net income for the period adjusted for non-cash items 3,598,624   4,034,715  
CHANGES IN NON-CASH WORKING CAPITAL ITEMS    
Trade receivables (696,335 ) 1,821,449  
Other receivables 62,702   (96,375 )
Inventories (322,192 ) (522,670 )
Prepaid expenses and deposits 137,618   12,471  
Accounts payable and accrued liabilities relating to operating activities 163,017   (355,552 )
Total changes in non-cash working capital items (655,190 ) 859,323  
Net income for the period adjusted for non-cash and working capital items 2,943,434   4,894,038  
Interest paid (106,390 ) (117,237 )
CASH GENERATED FROM OPERATIONS 2,837,044   4,776,801  
INVESTING ACTIVITIES    
Purchase of property and equipment (494,833 ) (222,610 )
Purchase of leasehold improvements (19,472 )  
Proceeds from sale of equipment 5,000   353  
Accounts payable and accrued liabilities relating to investing activities (132,994 ) 14,161  
CASH USED IN INVESTING ACTIVITIES (642,299 ) (208,096 )
FINANCING ACTIVITIES    
Stock options exercised 26,725   3,013  
Repayment of long-term debt   (112,973 )
Repayment of lease liabilities (180,285 ) (197,537 )
CASH USED IN FINANCING ACTIVITIES (153,560 ) (307,497 )
Increase in cash and cash equivalents 2,041,185   4,261,208  
     
Cash and cash equivalents at beginning of the period 5,369,029   1,857,195  
     
Cash and cash equivalents at end of the period 7,410,214   6,118,403  
     

The complete financial statements are available for review on SEDAR at https://sedar.com/Ceapro and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

This press release does not express or imply that the Company claims its product has the ability to eliminate, cure or contain the SARS-2-CoV-2 (COVID-19) at this time.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: Ceapro Inc.

Release – Comtech Telecommunications Corp. Awarded $1.8 Million Contract for High-Power Solid-State Amplifiers


Comtech Telecommunications Corp. Awarded $1.8 Million Contract for High-Power Solid-State Amplifiers

 

MELVILLE, N.Y.–(BUSINESS WIRE)–Nov. 17, 2021– 
November 17, 2021— 
Comtech Telecommunications Corp. (NASDAQ: CMTL), a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today, that during its first quarter of fiscal 2022, it was awarded an additional contract valued at 
$1.8 million for RF microwave solid-state amplifiers from a major domestic prime contractor.

These very high-power solid-state amplifiers, which utilize the latest in GaN transistor technology, were developed in close cooperation with the prime contractor and are part of a complex RF microwave transmission system used by the 
U.S. military.

“This additional contract award is another example of Comtech’s technical strength in delivering high-power solid-state transmitter solutions for military applications and the ongoing demand for our high-power solid-state amplifier products,” said  Fred Kornberg, Chairman of the Board and Chief Executive Officer of 
Comtech Telecommunications Corp.

The contract was awarded to 
Comtech PST Corp. (www.comtechpst.com) which is a leading independent supplier of high-power, high performance RF microwave amplifiers, transmitters and control components for use in a broad spectrum of applications including defense, medical, satellite communications systems and instrumentation.

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in 
Melville, New York and with a passion for customer success, 
Comtech designs, produces and markets advanced and secure wireless solutions. For more information, please visit www.comtechtel.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

Comtech Investor Relations:
631-962-7005
investors@comtech.com

Source: 
Comtech Telecommunications Corp.

Release – Schwazze Signs Definitive Agreement to Acquire MCG LLC


Schwazze Signs Definitive Agreement to Acquire MCG, LLC

 

Schwazze Continues its Colorado Expansion Strategy with Emerald Fields Cannaboutique Dispensaries in Manitou Springs & Glendale, CO

 

DENVER, Nov. 16, 2021 /CNW/ – Schwazze, (OTCQX: SHWZ) (“Schwazze” or the “Company”), announced that it has signed definitive documents to acquire MCG, LLC (“Emerald Fields”).  Emerald Fields owns and operates two retail cannabis dispensaries, located in Manitou Springs and Glendale, Colorado.  This acquisition is part of the Company’s continuing retail expansion plan in Colorado bringing the total number of dispensaries including announced acquisitions to 22.

Total consideration for the acquisition will be $29 million and will be paid as 60% cash and 40% Schwazze common stock upon closing.  The acquisition is targeted to close in the next 75 days, subject to closing conditions and covenants customary for this type of transaction, including, without limitation, obtaining Colorado Marijuana Enforcement Division and local licensing approval.

“Our team is delighted to add the Emerald Fields Cannaboutiques to our growing portfolio of dispensaries and are eager to welcome the team to Schwazze. Manitou Springs and Glendale are attractive locations and are valuable assets to our overall acquisitions plans as we continue to build out Colorado.  Our team is excited to add another store brand to our house of brands.”  said Justin Dye, Schwazze’s CEO.

About Schwazze
Schwazze (OTCQX: SHWZ) is building the premier vertically integrated cannabis company in Colorado and plans to take its operating system to other states where it can develop a differentiated leadership position.  Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.  The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition.  Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes.  The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.  Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.  Medicine Man Technologies, Inc. was Schwazze’s former operating trade name.  The corporate entity continues to be named Medicine Man Technologies, Inc.

Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “plan,” “will,” “may,”, “predicts,” or similar words. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to consummate the acquisition described in this press release or to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, * the timing and extent of governmental stimulus programs, and (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

SOURCE Schwazze

 

Great Lakes Dredge Dock (GLDD) – Windward Ho FID on Jones Act Offshore Wind Installation

Wednesday, November 17, 2021

Great Lakes Dredge & Dock (GLDD)
Windward Ho! FID on Jones Act Offshore Wind Installation

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The company only’s operating segments is Dredging. Dredging involves the enhancement or preservation of navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand or rock. Its projects portfolio includes Coastal Restoration, Coastal Protection, Port expansion, and others.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Final investment decision (FID) reached and shipyard engaged to build first Jones Act qualified incline fallpipe rock installation barge. Yesterday, a contract for $197 million was announced with Philly Shipyard, a publicly traded Norwegian company that is majority owned by Aker Capital. The goal is to construct the first Jones Act complaint vessel to assist in the installation of the wind turbine towers in US offshore areas beginning in 2025. The primary function of the rock dumping barge will be the placement of rock around the wind tower foundations for scour protection. The state of the art vessel will have all of the latest technology and should be well positioned to serve a growing market. Given the likelihood of government support (federal/state/local) for high local content on the construction of offshore wind farms, the outlook for this type of vessel appears promising.

    Payment schedule is favorable.  The shipyard contract has attractive payment terms that spread out the significant capex commitment over the next three years. A deposit of ~$15 million (8%) will paid in 4Q2021 and the remainder will be spread out over the next three years, with ~$35 million (18%) in 2022, ~$80 million (41%) in 2023 and $67 million (33%) in 2024. Owner furnished equipment in the $20 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

TAAL Distributed Information Technologies (TAALF) – Strong 3Q21 Raising PT

Wednesday, November 17, 2021

TAAL Distributed Information Technologies (TAALF)
Strong 3Q21; Raising PT

Taal Distributed Information Technologies Inc delivers value-added blockchain services, providing professional-grade, highly scalable blockchain infrastructure and transactional platforms to support businesses building solutions and applications upon the Bitcoin SV platform, and developing, operating, and managing distributed computing systems for enterprise users.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    3Q21 Results. TAAL had previously pre-announced 3Q revenue in the $11.5-$12.0 million (CAD) range. Actual revenue came in at $12.4 million, with income before value adjustments of $8.0 million, adjusted EBITDA of $3.9 million, and net income of $2.1 million, or $0.05 per share. We had projected revenue of $8 million, income before value adjustments of $4.8 million, and a net loss of $725,000, or $0.02 per share.

    Transactions.  TAAL processed over 52 million transactions on BSV in the quarter, earning $411,000 from transaction processing fees in the quarter, or 3% of total revenue. While mining continues to be the near-term revenue driver, we expect transaction fees to be the long-term value driver of the stock …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.